Research & Development: Targeted-gene Silencing BRAF


by | Dec 4, 2020

Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem


Melanoma is significantly associated with mutant BRAF gene, a suitable target for siRNA-based anti-melanoma therapy. However, a tumor-specific delivery system is a major hurdle for clinical applications. Here, we developed a novel nano-carrier, FA-GNR-siBRAF for safe topical application, which consists of folic acid (FA) as the tumor-targeting moiety, golden nanorods (GNR) providing photothermal capability to kill tumor cells under laser irradiation, and siRNA specifically silencing BRAF (siBRAF).

The in vitro and in vivo results revealed that FA-GNR-siBRAF displayed high transfection rates, and subsequently induced remarkable gene knockdown of BRAF, resulting in suppression of melanoma growth due to the interruption of the MEK/ERK pathway. Combinatorial photothermal effects and BRAF knockdown by FA-GNR-siBRAF effectively killed tumor cells through apoptosis, with enhanced efficiency than individual treatments.

Therefore, the FA-GNR-siBRAF simultaneously induced BRAF gene silencing and photothermal effects which achieved synergistic efficacy in the treatment of melanoma, paving a new path for developing clinical treatment methods for melanoma.

Author Contributions

Yujuan Zhang PhD, Xuelin Zhan MSc, Shanshan Peng MSc, Ying Cai PhD, Shrike Zhang PhD, Yanling Liu PhD, Zhigang Wang PhD, Yanrong Yu MSc Yifan Wang MD, Qiaofa Shi PhD, Xiaoping Zeng PhD, Keng Yuan MD, Nanjin Zhou MD, Rakesh Joshi PhD, Meng Zhang MSc, Zhuxu Zhang PhD, Weiping Min MD, PhD

Two Centimetres

Two Centimetres

The grueling ten-month journey into Ontario’s healthcare bureaucracy to get a melanoma removed from a woman’s neck. Part 1: The BumpThe origin story of any skin cancer diagnosis typically begins like this: “Hmph. I wonder what that is?” and is usually followed by “Do...

read more

Get In touch

Share This